Document is current

Article History

Accepted: 31 October 2024

First Online: 19 November 2024

Declarations

:

: This study was funded by Gilead Sciences, Inc.

: All authors are stockholders and either current or past employees of Gilead Sciences, Inc.

: The dataset supporting the results of this study is available upon reasonable request. Inquiries can be directed to the corresponding author.

: The trial was conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation good clinical practice guidelines, consistent with the requirements of the US Code of Federal Regulations Title 21, Part 312, the European Community Directive 2001/20/EC, and other local legislation. This study was approved by a duly constituted independent ethics committee or institutional review board at each study site (approval number, date: Pro00046464, 15 Sep 2014; SSU00132267, 28 Sep 2020; SSU00132670, 30 Oct 2020; SSU00134955, 2 Nov 2020; SSU00135391, 17 Nov 2020; SSU00135407, 17 Nov 2020; SSU00135579, 18 Nov 2020; SSU00136760, 23 Nov 2020; SSU00132957, 4 Mar 2021; SSU00133322, 9 Mar 2021; SSU00144548, 10 Mar 2021; 705/20 Af-KK, 9 Feb 2021; 20/CEN/248, 10 December 2020).

: Informed written consent was obtained from all participants before study participation.

: All study participants provided consent for publication.

: Not applicable.

: Haeyoung Zhang, Rita Humeniuk, Yiannis Koullias, and Robert H. Hyland contributed to the design of the study. Haeyoung Zhang, Sean Regan, Amy John, and Deqing Xiao contributed to the acquisition of data. Haeyoung Zhang, Sean Regan, Yiannis Koullias, Santosh Davies, and Gong Shen analyzed the data. Haeyoung Zhang, Rita Humeniuk, Yiannis Koullias, Santosh Davies, Robert H. Hyland, Helen Winter, and Aryun Kim contributed to the interpretation of the data. All authors critically reviewed the manuscript and approved the final manuscript for submission.